4th EASO Masterclass in Clinical Oncology
30 ESCO credits
20.06.2014 - 22.06.2014
Casablanca, Morocco
MASTERCLASS
Description
Chair: R. Gaafar, EG - N. Pavlidis, GR
Host Chair: A. Benider, MA
Host Chair: A. Benider, MA
General information
ORGANISING SECRETARIAT
Daniela Mengato
Euro-Arab School of Oncology (EASO)
Via Turati 29
20121 - Milan, Italy
Ph: +39 02 85464523
Fax: +39 0285464545
Email: easo@eso.net
VENUE
Golden Tulip Farah Casablanca
160, Av Des Forces Armees Royales
Casablanca - Morocco
Tel: +212 5 22 311212
www.goldentulipfarahcasablanca.com
OFFICIAL LANGUAGE
The official language of the course will be English and fluency in English is necessary for admission. No simultaneous translation will be provided.
BADGE
The badge is the only official evidence of registration and should be worn at all times during the masterclass. Loss of badge means loss of registration.
INSURANCE
The organisers bear no responsibility for untoward events in connection with, before, during and after the course. Participants are strongly advised to take out their own personal and travel insurance coverage.
IDEAL MASTERCLASS CANDIDATE
- Age up to 40 years
- 2-3 years’ experience mainly in clinical oncology
- Involvement in scientific activities
- Fluency in English
Daniela Mengato
Euro-Arab School of Oncology (EASO)
Via Turati 29
20121 - Milan, Italy
Ph: +39 02 85464523
Fax: +39 0285464545
Email: easo@eso.net
VENUE
Golden Tulip Farah Casablanca
160, Av Des Forces Armees Royales
Casablanca - Morocco
Tel: +212 5 22 311212
www.goldentulipfarahcasablanca.com
OFFICIAL LANGUAGE
The official language of the course will be English and fluency in English is necessary for admission. No simultaneous translation will be provided.
BADGE
The badge is the only official evidence of registration and should be worn at all times during the masterclass. Loss of badge means loss of registration.
INSURANCE
The organisers bear no responsibility for untoward events in connection with, before, during and after the course. Participants are strongly advised to take out their own personal and travel insurance coverage.
IDEAL MASTERCLASS CANDIDATE
- Age up to 40 years
- 2-3 years’ experience mainly in clinical oncology
- Involvement in scientific activities
- Fluency in English
Faculty list
FACULTY
N. Allahloubi, National Cancer Institute, Cairo University, EG
H.A. Azim Jr., Institut Jules Bordet, Breast Data Centre, Brussels, BE
N. Benchakroun, Centre Hospitalier Universitaire, IBN Rochid, Casablanca, MA
A. Benider, Centre Mohamed VI pour le Traitement du Cancer, Casablanca, MA
N. Benjaafar, National Institute of Oncology, Rabat, MA
G. Ceresoli, Istituto Humanitas Gavazzeni, Bergamo, IT
M. Di Maio, National Cancer Institute, Naples, IT
C. Doglioni, San Raffaele Scientific Institute, Milan, IT
H. Errihani, National Institute of Oncology, Rabat, MA
R. Gaafar, National Cancer Institute, Cairo University, EG
R. Garcìa Carbonero, Hospital Universitario Virgen Del Rocio, Sevilla, ES
F. Geara, American University of Beirut Medical Center, LB
H. Jouhadi, Centre Hospitalier Universitaire, IBN Rochid, Casablanca, MA
J. Khader, King Hussein Cancer Centre, Amman, JO
H. Khaled, National Cancer Institute, Cairo University, EG
R. Labianca, Ospediali Riuniti, Bergamo, IT
O. Michielin, Lausanne University Hospital - CHUV, Lausanne, CH
A. Morsi, National Cancer Institute, Cairo University, EG
O. Pagani, Oncology Institute of Southern Switzerland, Bellinzona, CH
N. Pavlidis, University of Ioannina, School of Medicine, Ioannina, GR
F. Peccatori, European Institute of Oncology, Milan, IT
A. Quessar, Centre Hospitalier Universitaire, IBN Rochid, Casablanca, MA
J. Romero-Otero, Hospital Universitario 12 de Octubre, Madrid, ES
S. Sahraoui, Centre Hospitalier Universitaire, IBN Rochid, Casablanca, MA
A. Shamseddine, American University of Beirut Medical Center, LB
M. Sughayer, King Hussein Cancer Centre, Amman, JO
N. Tawfiq, Centre Hospitalier Universitaire, IBN Rochid, Casablanca, MA
J.B. Vermorken, University Hospital of Antwerp, Edegem, BE
O.Z. Youssef, National Cancer Institute, Cairo University, EG
E. Zucca, Oncology Institute of Southern Switzerland, Bellinzona, CH
.
Programme
| 20 June | |||
| 8:10 | Welcome address R. Gaafar, EG - N. Pavlidis, GR | ||
| 8:15 | Introduction: The Euro-Arab School of Oncology (EASO): Eight years of activity N. Pavlidis, GR | ||
| LUNG CANCER Chairs: R. Gaafar, EG - N. Benjaafar, MA | |||
| 8:30 | The contribution of molecular pathology in the diagnosis and treatment of lung cancer M. Sughayer, JO | ||
| 9:00 | Radiation treatment of lung cancer: an update F. Geara, LB | ||
| 9:30 | Targeted therapy of advanced non-small cell lung cancer R. Gaafar, EG | ||
| 10:00 | Tumour board (2-3 cases) | ||
| 11:00 | Prayer and lunch break | ||
| COLORECTAL CANCER Chairs: R. Labianca, IT - N. Tawfiq, MA | |||
| 14:00 | The principles of surgery in colorectal cancer A. Morsi, EG | ||
| 14:30 | Adjuvant and neoadjuvant therapy of colorectal cancer R. Labianca, IT | ||
| 14:50 | The role of radiotherapy in the management of rectal and anal cancer J. Khader, JO | ||
| 15:20 | Systemic treatment of colorectal cancer in metastatic disease R. Labianca, IT | ||
| 15:50 | Tumour board (2 cases) | ||
| 16:30 | Coffee break | ||
| Chairs: R. Garcia-Carbonero, ES - N. Tawfiq, MA | |||
| 17:00 | Spotlight: the management of GI neuroendocrine tumours Speaker to be confrimed | ||
| 17:30 | Spotlight: treatment of hepatocellular carcinoma: is there any progress? M. Di Maio, IT | ||
21 June
| |||
| BREAST CANCER Chairs: O. Pagani, CH - H. Errihani, MA | |||
| 8:30 | The role of surgery in breast cancer O.Z. Youssef, EG | ||
| 9:00 | The role of gene expression signatures in adjuvant breast cancer H.A. Azim Jr., BE | ||
| 9:30 | Indications of radiation therapy in early breast cancer F. Geara, LB | ||
| 10:00 | Neoadjuvant and adjuvant chemotherapy and targeted treatments O. Pagani, CH | ||
| 10:30 | Neoadjuvant and adjuvant hormonal therapy treatment N. Allahloubi, EG | ||
| 11:00 | Coffee break | ||
| 11:30 | Systemic treatment of advanced disease O. Pagani, CH | ||
| 12:30 | Breast cancer in young women: impact of pregnancy on biology and outcome F. Peccatori, IT | ||
| 12:30 | Tumour board (2-3 cases) | ||
| 13:30 | Lunch break | ||
| PROSTATE CANCER Chairs: A. Shamseddine, LB - H. Jouhadi, MA | |||
| 14:30 | The principles of surgery in prostate cancer J. Romero-Otero, ES | ||
| 15:00 | Radiation therapy of prostate cancer J. Khader, JO | ||
| 15:30 | Systemic treatment in prostate cancer A. Shamseddine, LB | ||
| 16:00 | Coffee break | ||
| 16:30 | Tumour board (2-3 cases) | ||
| 22 June | |||
| LYMPHOMA Chairs: E. Zucca, CH - A. Quessar, MA | |||
| 8:30 | What the clinical oncologist needs from the pathologist? C. Doglioni, IT | ||
| 9:00 | Management of low grade lymphoma H. Khaled, EG | ||
| 9:30 | Management of high grade lymphoma E. Zucca, CH | ||
| 10:00 | Tumour board (2-3 cases) | ||
| 11:00 | Coffee break | ||
| GYNAECOLOGICAL CANCERS Chairs: J. Vermorken, NL - S. Sahraoui, MA | |||
| 11:30 | Systemic management of epithelial ovarian cancer: where do we stand today? J. Vermorken, NL | ||
| 12:00 | Systemic therapy of cervical carcinoma: any progress ? J. Vermorken, NL | ||
| 12:30 | Tumour board (2-3 cases) | ||
| 13:30 | Spotlight: Cancer of unknown primary N. Pavlidis, GR | ||
| 14:00 | Lunch break | ||
| Chairs: G. Ceresoli, IT - N. Benchakroun, MA | |||
| 15.00 | Spotlight: Renal cancer G. Ceresoli, IT | ||
| 15:30 | Spotlight: Current treatment and perspective in stage IV melanoma O. Michielin, CH | ||
| 16:00 | Exam | ||
| 17:00 | Closing remarks | ||